PFE

Pfizer
D

PFE

Arincen59/100B
29.390
USD
-0.49
(-1.64%)
Post Trading·29.320USD-0.070(-0.24%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.72Revenue estimate 17.14B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Pfizer net income 1985–2026

Pfizer earned 3.24B USD in Q3 FY2026, the three months to 27 September 2026, down 8.4% on the same quarter a year before. Pfizer's net income over the last twelve months was 4.03B USD, down 59.0% on the twelve months before. In fiscal year 2025 it earned 7.77B USD, down 3.2% on the year before.

Last updated 3 Nov 2026 · Next report 2 Feb 2027

Net income

Net income · +1.1% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM27 Sept 20264.03B-58.96%6.34%63.62B
FY202531 Dec 20257.77B-3.24%12.42%62.58B
FY202431 Dec 20248.03B+279.00%12.62%63.63B
FY202331 Dec 20232.12B-93.25%3.56%59.55B
FY202231 Dec 202231.37B+42.74%31.01%101.18B
FY202131 Dec 202121.98B+139.97%27.04%81.29B
FY202031 Dec 20209.16B-42.85%21.99%41.65B
FY201931 Dec 201916.03B+43.69%39.18%40.91B
FY201831 Dec 201811.15B-47.66%27.32%40.83B
FY201731 Dec 201721.31B+195.33%40.55%52.55B
FY201631 Dec 20167.22B+3.66%13.66%52.82B
FY201531 Dec 20156.96B-23.81%14.25%48.85B
FY201431 Dec 20149.14B-58.48%18.42%49.61B
FY201331 Dec 201322.00B+51.02%42.65%51.58B
FY201231 Dec 201214.57B+45.57%26.66%54.66B
FY201131 Dec 201110.01B+21.22%16.40%61.04B
FY201031 Dec 20108.26B-4.38%12.67%65.17B
FY200931 Dec 20098.64B+6.55%17.27%50.01B
FY200831 Dec 20088.10B-0.49%16.78%48.30B
FY200731 Dec 20078.14B-57.88%16.82%48.42B
FY200631 Dec 200619.34B+139.17%39.98%48.37B
FY200531 Dec 20058.09B-28.84%17.06%47.41B
FY200431 Dec 200411.36B+190.56%23.19%48.99B
FY200331 Dec 20033.91B-57.16%8.74%44.74B
FY200231 Dec 20029.13B+17.18%28.26%32.29B
FY200131 Dec 20017.79B+109.02%26.83%29.02B
FY200031 Dec 20003.73B-24.76%12.69%29.36B
FY199931 Dec 19994.95B+6.89%18.09%27.38B
FY199831 Dec 19984.63B+109.35%19.94%23.23B
FY199731 Dec 19972.21B+14.72%20.02%11.06B
FY199631 Dec 19961.93B+22.64%19.56%9.86B
FY199531 Dec 19951.57B+21.14%15.70%10.02B
FY199431 Dec 19941.30B+97.48%15.68%8.28B
FY199331 Dec 1993657.50M-18.92%8.79%7.48B
FY199231 Dec 1992810.90M+12.30%11.22%7.23B
FY199131 Dec 1991722.10M-9.87%10.39%6.95B
FY199031 Dec 1990801.20M+17.63%12.51%6.41B
FY198931 Dec 1989681.10M-13.93%12.01%5.67B
FY198831 Dec 1988791.30M+14.65%14.69%5.39B
FY198731 Dec 1987690.20M+4.58%14.03%4.92B
FY198631 Dec 1986660.00M+13.85%14.75%4.48B
FY198531 Dec 1985579.70M—14.40%4.02B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Pfizer's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.